Tofacitinib-Induced Dyslipidemia Mechanism

Introduction to Tofacitinib's Effects on Lipid Metabolism

• Chronic inflammation in immune-mediated diseases actively suppresses lipid levels through IL-6-mediated pathways, enhancing sterol regulatory element binding proteins (SREBPs), reducing lipase expression, and increasing intestinal permeability, leading to altered lipid metabolism in patients with rheumatoid arthritis, according to the American Heart Association 1

Mechanism of Action

• Tofacitinib blocks IL-6 receptor signal transduction by inhibiting JAK1 and JAK2, which is the primary mechanism of efficacy in rheumatoid arthritis, as stated by the European League Against Rheumatism 2

Clinical Implications

• Lipid monitoring should occur at 1-2 months after initiating tofacitinib, then every 6 months or annually, as recommended by the American College of Rheumatology 4
• Major adverse cardiovascular events (MACE) remain infrequent with tofacitinib in immune-mediated inflammatory diseases, with incidence rates of 0.24-0.37 per 100 patient-years, as reported by the National Institute of Health 6

Dyslipidemia Mechanism

• The dyslipidemia mechanism differs fundamentally from glucocorticoid-induced dyslipidemia, which increases VLDL and triglyceride production through different pathways, as noted by the American College of Cardiology 1
• Liver enzyme elevations >3 times the upper limit of normal can occur alongside lipid changes and require monitoring, according to the National Institute of Health 3